Sonrotoclax TFA
Sonrotoclax TFA is a potent, selective, and orally bioavailable BCL-2 inhibitor targeting both wild-type and G101V mutant proteins. It is utilized in preclinical research for hematologic malignancies, demonstrating antitumor activity in both in vitro cellular assays and in vivo xenograft models.
Product Specifications
Product Name Alternative
BGB 11417 TFA, Bcl-2, Sonrotoclax TFA (2383086-06-2 Free base), SonrotoclaxTFA (2383086062Freebase)
Field of Research
Cell Biology, Immunology & Inflammation
Purity
99.63% (May vary between batches)
Smiles
CC (C1=C (C=CC=C1) [C@H]2N (CCC2) C3CC4 (CCN (C5=CC (OC6=CN=C (NC=C7) C7=C6) =C (C=C5) C (NS (=O) (C8=CC (N (=O) =O) =C (C=C8) NC[C@@H]9CC[C@@] (O) (CC9) C) =O) =O) CC4) C3) C.OC (C (F) (F) F) =O
Molecular Formula
C51H60F3N7O9S
Molecular Weight
1004.12
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
